FDA Approves Pixclara, First FET-PET Imaging Drug for Glioma Brain Cancer

The U.S. Food and Drug Administration (FDA) has approved Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer). This marks the first FDA-approved FET-PET imaging drug for glioma, addressing a critical unmet need by assisting physicians in differentiating recurrent or progressive glioma from treatment-related changes in both adult and pediatric patients. FET-PET imaging is already recognized in international clinical practice guidelines.